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Background: In developing countries, access to laboratory tests remains limited, and
the use of simple tools such as weight to monitor HIV-infected patients treated with
antiretroviral therapy should be evaluated.
Methods: Cohort study of 2451 Cambodian and 2618 Kenyan adults who initiated
antiretroviral therapy between 2001 and 2007. The prognostic value of weight gain
at 3 months of antiretroviral therapy on 3–6 months mortality, and at 6 months on
6–12 months mortality, was investigated using Poisson regression.
Results: Mortality rates [95% conﬁdence interval (CI)] between 3 and 6 months of
antiretroviraltherapywere9.9(7.6–12.7)and13.5(11.0–16.7)per100person-yearsin
Cambodia and Kenya, respectively. At 3 months, among patients with initial body mass
index less than or equal to 18.5kg/m
2 (43% of the study population), mortality rate
ratios (95% CI) were 6.3 (3.0–13.1) and 3.4 (1.4–8.3) for those with weight gain less
than or equal to 5 and 5–10%, respectively, compared with those with weight gain of
more than 10%. At 6 months, weight gain was also predictive of subsequent mortality:
mortality rate ratio (95% CI) was 7.3 (4.0–13.3) for those with weight gain less than or
equal to 5% compared with those with weight gain of more than 10%.
Conclusion: Weight gain at 3 months is strongly associated with survival. Poor
compliance or undiagnosed opportunistic infections should be investigated in patients
with initial body mass index less than or equal to 18.5 and achieving weight gain less
than or equal to 10%.  2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
In 2007, over 22 million people were estimated to be
HIV-infected in sub-Saharan Africa, and approximately
4 million in South-east Asia [1]. Following the World
Health Organisation (WHO) ‘3 by 5’ initiative aimed at
providing antiretroviral therapy (ART) to 3 million
individuals by 2005 [2], tremendous efforts have been
made to increase ART access in resource-limited
countries [3,4], and programmes providing ART in such
settings have proved their efﬁciency [5–9].
Scaling up ART resulted in the rapid increase of the
number of patients entering and requiring long-term
HIV care. Decentralization of HIV care through nurses
and clinical ofﬁcers is one of the key elements for wider
accessto ART toovercomephysician shortages[3,10,11].
Experience from several resource-limited countries
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where HIV care is provided by nurses and/or clinical
ofﬁcers has been successful [3,4], but requires simpliﬁed
and standardized follow-up of HIV-infected patients
[12]. In such settings, in which access to laboratory tests
remains limited, identifying simple tools to monitor
disease progression is important [13–16]. Weight gain/
lossisonepotentialtool,asitiseasilymeasurableandcosts
little. Indeed, body mass index (BMI) at ART initiation is
astrongpredictorofdiseaseprogression[7,17,18],andthe
proportion of patients achieving weight gain of at least
10%6monthsafterARTinitiationisoneoftheindicators
proposed by WHO to evaluate HIV programmes [19].
In developed countries, little attention has been paid to
the evolution of weight under ART, and studies have
reported only moderate increases [20,21]. However,
weight loss was found to be associated with increased
mortality [22,23]. In resource-limited settings, in which
patients initiate treatment at a more advanced stage of
disease [6,7], weight gain under ART might be greater.
Researchers from India reported a mean weight increase
of 2.5kg after 6 months under nevirapine-based therapy
[24] but did not investigate its prognostic value on
disease progression.
Our goals were to describe weight gain in patients
on ART enrolled in Me ´decins Sans Frontie `res
(MSF) programmes in two resource-limited countries
(Cambodia and Kenya), and to evaluate the prognostic
value of weight gain on mortality to determine whether
itcouldbeusedasamonitoringtoolforpatientsonART.
Methods
Study population
Study participants were patients treated with ART (ART
was deﬁned as three or more antiretroviral drugs,
irrespective of their class) in two MSF programmes based
at the Khmero-Soviet Friendship Hospital of Phnom
Penh, Cambodia, and the district hospital of Homa Bay,
Kenya. In both programmes, following WHO recom-
mendations, ART initiation criteria were a WHO stage
4 condition, WHO stage 3 condition with CD4 cell
count less than 350cells/ml, or a CD4 cell count less
than 200cells/ml. Patients were seen monthly the ﬁrst
6 months following ART initiation, then every 2 months
if stable. At each visit, patients underwent an interview
and clinical examination, with the corresponding data
routinely entered into the FUCHIA database (Epicentre,
Paris, France).
Patients included in this analysis were ART-naive adults
( 18 years), in whom weight was recorded at ART
initiation and at least once during follow-up, and with a
minimum follow-up of 3 months on ART. Thus, 344
Cambodians and 277 Kenyans were not considered
because of a follow-up less than 3 months (in Cambodia:
135 deaths, 28 lost to follow-up, and 181 ART initiation
within3monthsfromcut-offdate12July2007;inKenya:
149 deaths, 119 lost to follow-up, nine ART initiation
within 3 months from cut-off date 26 January 2007).
Only patients who initiated ART before 1 January 2006
in Kenya were included, as no nutritional supplement-
ation was provided before this date. We excluded women
enrolled in mother-to-child prevention programmes, as
well as 13 patients from Kenya who interrupted their
follow-up for  18 months. A total of 2451 patients from
Phnom Penh and 2618 patients from Homa Bay were
considered for the analysis.
Weight measurements
Eligible patients contributed a total number of 58654
visits in Cambodia and 50703 visits in Kenya during
the entire follow-up; median follow-up were 45 and
32 months in Cambodia and Kenya, respectively. In 190
(0.3%) and 683 (1.3%) visits in Cambodia and Kenya,
respectively, weight was not recorded.
We validated and eliminated inconsistencies in weight
measurements ﬁrst by identifying 49 patients with low
(<25kg) weight measurements. In 33 of these patients,
these weights were inconsistent (>10kg difference with
other weight measurements) and were then considered
as missing; in the remaining 16 patients, weight
was consistent with other measurements. Secondly, we
identiﬁed 23 patients with a weight difference of at least
10kg between two consecutive visits separated by less
than1week;theseweight measurementswereconsidered
as missing. Finally, in 99 patients, a weight difference of at
least 15kg within 3 months was observed. Of these
patients, 70 presented a weight difference of 15kg or
more with both the previous and the next visit, but
the differences being in opposite directions; the middle
weight measurement was thus considered missing. In the
remaining 29 patients, weight was consistent with the
other measurements. After exclusion of inconsistent
weight values, missing weight measurements [243 (0.4%)
and 702 (1.4%) in Cambodia and Kenya, respectively]
were estimated through linear extrapolation using
adjacent weight measurements.
Weight gain at 3 or 6 months was expressed as the
percentage gained with respect to the weight measured at
ART initiation, using the closest measurement to 3 or
6 months.
Sensitivity analyses were performed deﬁning weight gain
with respect tothemean of thetwoweightmeasurements
obtained within 1month after ART initiation, which was
available for 94 and 68% of patients in Cambodia and
Kenya,respectively.Thesecondweightmeasurementwas
larger than the ﬁrst in 40 and 50% of the patients,
respectively. Similarly, alternative weight gain at 3 or
6 months was estimated using the mean weight of all
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measurements recorded within the 2-month interval
around the third or sixth month.
Laboratory tests
AtARTinitiation,andthenevery6months,wholeblood
sampleswere collected for total lymphocyte and CD4 cell
counts. In Cambodia, CD4 measurements were per-
formed until 2005 at the Institut Pasteur in Phnom Penh
and then at the national Public Health Institute of Phnom
Penh using FACSCalibur ﬂow cytometry technology
(BD Biosciences, Immunocytometry Systems, San Jose,
California, USA). In Kenya, CD4 measurements were
performed at the Homa Bay district hospital using
FACSCount (Becton Dickinson Immunocytometry
Systems, San Jose, California, USA).
Statistical analysis
Median weight gains at different time points were
calculated by BMI level at ART initiation deﬁned in four
categories ( 17, >17 and  18.5, >18.5 and  20, and
>20kg/m
2), the ﬁrst two categories representing severe-
to-moderate and mild malnutrition, respectively [25,26].
To describe the weight gain evolution, we used a
nonparametric method: locally weighted smoothed
spline (LOWESS) curves which draw a representative
smooth curve through data using robust local regression
[27].
The prognostic value of weight gain at 3 and at 6 months
of ARTon short-term mortality (within the following 3
and 6 months, respectively) was investigated using
Poisson regression models. These time points were
chosenastheyrepresentimportantvisitsinthefollow-up
of patients. Weight gains achieved were categorized as
lessthanorequalto5%,morethan5andlessthanorequal
to 10%, and more than 10%. We ﬁrst investigated the
prognostic value of weight gain, by programme and by
BMI level at ART initiation. Interaction effects between
weight gain and programme, and between weight gain
and BMI level at ART initiation, were assessed. The
prognostic value of weight gain was then evaluated in a
multivariate Poisson model adjusting for confounding
factors.
Finally, we described the time to reach weight gain more
than 10% using Kaplan–Meier estimates. In patients who
achieved weight gain more than 10%, we described the
time until a weight measurement was lower or equal to
the weight at ART initiation using Kaplan–Meier
estimates, and estimated the prognostic value of this
weight loss on mortality using a Cox model.
Statistical analyses were performed using Stata 8 (Stata
Corp.,CollegeStation,Texas,USA).Allsigniﬁcancetests
were two-sided and P values less than 0.05 were
considered signiﬁcant.
Results
In this analysis, 2451 patients from Cambodia and 2618
patients from Kenya were included. The proportion of
men was signiﬁcantly higher in Cambodia than in Kenya
(54 and 37%, respectively, P<0.001). In both pro-
grammes, nearly all patients were in WHO stage 3 or 4 at
ART initiation (Table 1), but Cambodian patients had
lower median CD4 cell counts than Kenyans (33 vs.
114cells/ml, respectively, P<0.001). Median BMI was
also lower in Cambodians than in Kenyans (18.8 vs. 19.4,
respectively, P<0.001), and the proportions of patients
with severe-to-moderate and mild malnutrition at ART
initiation were 27 and 19%, respectively, in Cambodia,
and 19 and 20%, respectively, in Kenya.
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Table 1. Patient characteristics at ART initiation by programme.
Cambodia (N¼2451) Kenya (n¼2618) P-value
Sex Men (%) 1324 (54.0) 969 (37.0) <0.001
Age (years) Median (IQR) 34 (30–40) 35 (30–42) <0.001
WHO clinical stage 1–2 (%) 236 (9.6) 89 (3.4) <0.001
3 (%) 1063 (43.4) 1276 (48.7)
4 (%) 1152 (47.0) 1253 (47.9)
CD4 cell count (cells/ml) N (%) 2304 (94.0) 1663 (63.5)
Median (IQR) 33 (8–115) 114 (57–170) <0.001
BMI (kg/m
2) N (%) 2122 (86.6) 2606 (99.5)
Median (IQR) 18.8 (16.9–20.8) 19.4 (17.6–21.2) <0.001
 17
a 569 (26.8) 500 (19.2)
17–18.5
b 408 (19.2) 514 (19.7)
18.5–20 426 (20.1) 530 (20.3)
>20 719 (33.9) 1062 (40.8)
ART regimen 3TC-d4T-NVP (%) 1249 (51.0) 2239 (85.5) <0.001
3TC-d4T-EFV (%) 1139 (46.5) 226 (8.6)
Other (%) 63 (2.5) 153 (5.9)
ART,antiretroviraltherapy;BMI,bodymassindex;d4T,stavudine;EFV,efavirenz;IQR,interquartilerange;NVP,nevirapine;WHO,WorldHealth
Organisation; 3TC, lamivudine.
aSevere-to-moderate malnutrition.
bMild malnutrition.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
In both programmes, ART consisted in a combination of
two nucleoside reverse transcriptase inhibitors (NRTI)
and one nonnucleoside reverse transcriptase inhibitor
(NNRTI). The most frequently prescribed ﬁrst-line
ARTregimens were lamivudine (3TC)-stavudine (d4T)-
nevirapine (NVP) (50.5% in Cambodia and 85.5% in
Kenya) and 3TC-d4T-efavirenz (EFV) (46.8% in
Cambodia and 8.6% in Kenya).
Weight gain under antiretroviral therapy
Body mass index level at ART initiation was associated
with the magnitude of subsequent weight gain, such that
patients with lower BMI had larger weight gains (Fig. 1).
Within each BMI category, observed weight gain was
larger in Kenyans than in Cambodians. Nevertheless,
LOWESS curves showed similar patterns of weight gain
in the two programmes and across BMI categories.
Hence, weight gain increased during the ﬁrst year of
ART and then remained stable or moderately increased
afterward.
At 3 months of ART, in the four BMI categories at ART
initiation – less than or equal to 17, more than 17 and less
than or equal to 18.5, more than 18.5 and less than or
equal to 20, and more than 20 – median [interquartile
range (IQR)] weight gains (in %) were 5.4 (0.0;13.3),
2.5 (0.0;8.0), 1.8 ( 1.8;5.4), and 0.0 ( 1.8;3.4) in
Cambodia; and 10.5 (2.2;19.6), 6.7 (1.9;12.3), 3.7
(0.0;7.7), and 1.8 ( 1.6;6.2) in Kenya. Similarly, in the
four BMI categories, median (IQR) weight gains at
6 months of ART (in %) were 12.5 (4.4;22.5), 6.5
(2.0;13.3), 4.0 (0.0;9.1), and 1.8 ( 1.9;6.1) in Cambodia;
and 18.8 (8.0;30.8), 11.9 (5.3;20.9), 8.0 (1.6;15.4), and
3.7 ( 0.7;8.7) in Kenya.
Prognostic value of weight gain at 3 months
Of the patients alive 3 months after ART initiation, 59
in Cambodia and 86 in Kenya died within the following
3 months corresponding to an overall mortality rate
[95% conﬁdence interval (CI)] of 9.9 (7.6–12.7) per 100
person-years in Cambodia and 13.5 (11.0–16.7) per 100
person-years in Kenya. During this period, 62 (2.1%) and
46 (1.8%) patients were lost to follow-up in Cambodia
and Kenya, respectively.
The prognostic value of weight gain at 3 months differed
according to BMI level at ART initiation, such that in
patients with BMI less than or equal to 18.5, those
achieving weight gain less than orequal to 5%, and those
achieving weight gain more than 5% and less than or
equal to 10% had an increased risk of death compared
with those with weight gain more than 10% [mortality
rate ratio (MRR) 4.8 (95% CI 2.3–10.1) and 2.6
(95% CI 1.1–6.4), respectively]. In patients with BMI
more than 18.5, weight gain was not associated with
mortality(P¼0.11)(Table2).Testingfor interaction,no
signiﬁcantdifferenceswerefoundintheprognosticvalue
of weight gain between men and women (P¼0.85),
between Kenya and Cambodia (P¼0.68), between
patientswithWHOclinicalstage4atARTinitiationand
other patients (P¼0.57), between CD4 categories at
ART initiation (P¼0.57), or between patients who
initiated a NVP-based or EFV-based combination
(P¼0.78).
After adjusting for other factors, weight gain at 3 months
remained strongly associated with mortality (Table 3).
Other baseline factors associated with higher mortality
were WHO stage 4 (compared with stage 3) and BMI.
Interestingly, CD4 cell count at ART initiation was no
longer associated with mortality.
Sensitivity analyses using the mean of the ﬁrst twoweight
measurements recorded within the ﬁrst month of ART
and/or deﬁning weight at 3 months as the mean of all
measurements recorded within the 2-month period
around the third month after ART initiation gave similar
results (data not shown).
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Fig. 1. Evolution of weight gain under ART in Cambodia (a)
and Kenya (b) programmes, by BMI at ART initiation. Plain
line: BMI less than or equal to 17kg/m
2 (severe-to-moderate
malnutrition). Dotted line: BMI more than 17 and less than or
equal to 18.5kg/m
2 (mild malnutrition). Dashed line: BMI
more than 18.5 and less than or equal to 20kg/m
2. Dashed-
dotted line: BMI more than 20kg/m
2. ART, antiretroviral
therapy.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Prognostic value of weight gain at 6 months
At 6 months, 2340 (95%) Cambodian and 2486 (95%)
Kenyan patients were still alive and followed up. Of these,
60 in Cambodia [mortality rate: 5.4 per 100 person-years
(95% CI 4.2–6.9)] and 82 in Kenya [6.8 (95% CI
5.5–8.5)] died within the following 6 months. During
this period, 47 (2.0%) and 163 (6.6%) patients were also
lost to follow-up in Cambodia and Kenya, respectively.
Weight gain at 6 months was predictive of mortality over
the 6–12-month period. However, as previously, the
prognostic value differed by BMI level at ART initiation,
such that in patients with severe-to-moderate and
mild malnutrition (BMI  18.5), a six-fold increase in
mortality was observed in those with weight gain less
than or equal to 5% (compared with those with weight
gain >10%), whereas no increased risk was observed in
patients with BMI more than 18.5 (P¼0.14) (Table 2).
As before, testing for interaction, no signiﬁcant
differences were found in the prognostic value of weight
gain at 6 months between sex (P¼0.09), between Kenya
and Cambodia (P¼0.98), between patientswho initiated
ART in WHO clinical stage 4 and other patients
(P¼0.35), between CD4 categories at ART initiation
(P¼0.41), and between patients who initiated a NVP-
based or EFV-based combination (P¼0.65).
Inpatientswithsevere-to-moderateandmildmalnutrition
at ART initiation, weight gain remained signiﬁcantly
associatedwithmortalityinamultivariatemodel(Table3).
OtherfactorsassociatedwithmortalitywereWHOstage4
(comparedwithstage3),severe-to-moderatemalnutrition
(comparedwithmildmalnutrition),andCD4cellcountat
6monthslessthanorequalto100cells/ml(comparedwith
CD4 101–200cells/ml).
Mortality after at least 10% weight gain
Median duration of follow-up on ARTwas 45 months in
Cambodia and 32 months in Kenya, and 3085 (60.9%)
patients experienced weight gain at least 10% on ART
(1369 and 1716 in Cambodia and Kenya, respectively).
Of these patients, 196 (6.4%) subsequently died.
Median delay (IQR) to reach aweight gain of at least 10%
wasshorter inKenyathaninCambodia:8.5(3.1–41.9)vs.
14.7 (4.6–63.4) months, respectively (P<0.001). This
delay in weight gain increased as BMI at ART initiation
increased;median delays in thefour BMI categories( 17,
>17and 18.5, >18.5,and 20,and>20) were3.8,6.0,
13.1, and 35.4 months, respectively (P<0.001).
Of the 3085 patients on ART with weight gain at least
10% during follow-up, 548 (17.8%) subsequently lost
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Table 2. Prognostic value of weight gain at 3 months of ART (M3) on mortality during the 3–6-month period, and at 6 months of ART (M6) on
mortality during the 6–12-month period, by BMI level at ART initiation.
BMI
(kg/m
2) Weight gain N Death PY
Mortality rate
(95% CI) MRR (95% CI) N Death PY
Mortality rate
(95% CI) MRR (95% CI)
M3
 17
a  5% 432 34 101.4 33.5 (24.0–46.9) 4.4 (2.0–9.5)
>5 and  10% 168 9 40.5 22.2 (11.6–42.7) 2.9 (1.1–7.6)
>10% 431 8 105.4 7.6 (3.8–15.2) 1 898 51 214.3 23.8 (18.1–31.3) 4.8 (2.3–10.1)
>17 and  5% 466 17 112.9 15.1 (9.4–24.2) 2.6 (0.8–9.0) 381 12 92.8 12.9 (7.3–22.8) 2.6 (1.1–6.4)
 18.5
b >5 and  10% 213 3 52.3 5.7 (1.8–17.8) 1 654 8 161.1 5.0 (2.4–9.9) 1
>10% 223 0 55.7 0.0 (0.0–6.6) –
>18.5 and  5% 619 11 151.3 7.2 (4.0–13.1) –
 20 >5 and  10% 199 0 49.1 0.0 (0.0–7.5) –
>10% 128 0 32.0 0.0 (0.0–11.5) – 1952 31 478.0 6.5 (4.6–9.2) 2.1 (0.5–8.9)
>20  5% 1333 20 326.7 6.1 (3.9–9.5) 1.0 (0.2–4.4) 490 2 121.0 1.7 (0.4–6.6) 0.5 (0.1–3.8)
>5 and  10% 291 2 71.9 2.8 (0.7–11.1) 0.5 (0.1–3.3) 264 2 65.6 3.0 (0.8–12.2) 1
>10% 136 2 33.6 5.9 (1.5–23.8) 1
M6
 17
a  5% 230 28 100.0 28.0 (19.3–40.6) 8.5 (4.2–17.9)
119 4 56.4 7.1 (2.7–18.9) 2.1 (0.6–7.0) >5 and  10% 546 46 246.6 18.7 (14.0–24.9) 6.0 (3.3–10.7)
>10% 609 10 295.4 3.4 (1.8–6.3) 1 289 4 138.5 2.9 (1.1–7.7) 0.9 (0.3–2.8)
>17 and  5% 316 18 146.6 12.3 (7.7–19.5) 5.6 (2.1–15.0) 988 15 479.5 3.1 (1.9–5.2) 1
 18.5
b >5 and  10% 170 0 82.1 0.0 (0.0–4.5) –
>10% 379 5 184.1 2.7 (1.1–6.5) 1
>18.5 and  5% 467 9 222.2 4.1 (2.1–7.8) 1.1 (0.4–3.2)
 20 >5 and  10% 188 3 91.2 3.3 (1.1–10.2) 0.8 (0.2–3.5)
>10% 252 5 123.3 4.1 (1.7–9.7) 1 1526 38 729.5 5.2 (3.8–7.2) 1.7 (0.8–3.7)
>20  5% 1059 29 507.3 5.7 (4.0–8.2) 2.5 (0.7–8.5) 537 7 259.7 2.7 (1.2–5.7) 0.9 (0.3–2.5)
>5 and  10% 349 4 168.5 2.4 (0.9–6.3) 1.1 (0.3–4.8) 544 8 265.2 3.0 (1.5–6.0) 1
>10% 292 3 141.9 2.1 (0.7–6.6) 1
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; MRR, mortality rate ratio; PY, person-years.
aSevere-to-moderate malnutrition.
bMild malnutrition.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
weight down to or below the weight recorded at ART
initiation. This delay in weight loss did not differ between
the two programmes (log rank, P¼0.43). In univariate
Cox regression, weight loss was associated with higher
mortality (Table 4). After adjustment for baseline
characteristics at ART start (WHO stage, CD4 count,
and BMI), weight loss remained signiﬁcantly associated
withhigher mortality[hazardratio6.6(95%CI4.7–9.3)].
Discussion
This study is of major importance for the management
of HIV-infected patients under ART in developing
countriesasitshowsthatweightgainisstronglyassociated
with survival. At 3 months, among patients with severe-
to-moderate or mildmalnutrition atART initiation (43%
of study population), those with weight gain of less than
or equal to 5% or more than 5 and less than or equal to
10% were, respectively, six-fold and three-fold more
likely to die within the next 3 months compared with
thosewithweightgainofmorethan10%.At6months,in
patients with severe-to-moderate or mild malnutrition at
ART initiation, the prognostic value of weight gain was
still high (MRR of 8), but only for those not achieving at
least 5% weight gain.
Because greater weight gain can be expected at 6 months
than at 3months of ART, it seems paradoxical that weight
gain of more than 5 and less than or equal to 10% would
be considered sufﬁcient at 6 months but not at 3 months.
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Table 3. Prognostic factors of mortality during 3–6 and 6–12-month periods after ART initiation, in patients with BMI< – 18.5 at ART initiation.
M3 to M6 mortality M6 to M12 mortality
Adjusted MRR (95% CI) Adjusted MRR (95% CI)
Full model Reduced model Full model Reduced model
Weight gain
a
 5% 6.5 (3.1–13.7) 6.3 (3.0–13.1) 7.6 (4.0–14.2) 7.3 (4.0 – 13.3)
>5 and  10% 3.4 (1.3–8.4) 3.4 (1.4–8.3) 1.1 (0.3–3.6) 1.1 (0.4 – 3.5)
>10% 1 1 1 1
Programme
Cambodia 1 1
Kenya 1.9 (0.9–3.7) 1.9 (0.9–4.0)
Sex
Men 1 1
Women 0.7 (0.4–1.2) 0.6 (0.3–1.0)
Age (years)
b
<30 1 1
30–39 1.4 (0.8–2.5) 0.8 (0.4–1.5)
40–49 0.8 (0.4–1.9) 0.9 (0.4–1.8)
 50 2.1 (0.9–5.1) 0.7 (0.2–2.2)
WHO clinical stage
b
31 1 1 1
4 4.1 (1.9–9.0) 4.9 (2.2–10.9) 2.0 (1.1–3.8) 2.3 (1.2–4.1)
BMI (kg/m
2)
b
 17
d 2.4 (1.4–4.0) 2.4 (1.4–4.0) 2.2 (1.3–3.7) 2.1 (1.2–3.5)
>17 and  18.5
e 11 1 1
TB diagnosed
c
No 1 1
Yes 1.3 (0.7–2.3) 1.5 (0.9–2.6)
Diarrhoea
c
No 1 1
Yes 1.9 (1.0–3.5) 1.5 (0.6–3.6)
CD4 cell count (cells/ml)
b
 50 0.9 (0.4–1.9)
51–100 1
>100 0.4 (0.1–1.3)
Missing 0.7 (0.3–1.8)
CD4 cell count at M6 (cells/ml)
 100 2.7 (1.0–7.0) 3.0 (1.2–7.6)
101–200 11
>200 1.7 (0.5–5.1) 1.7 (0.6–4.7)
Missing 3.1 (1.1–8.8) 3.7 (1.5–8.8)
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; MRR, mortality rate ratio; TB, tuberculosis; WHO, World Health
Organisation. Bold: signiﬁcant covariate (P<0.05).
aMeasured at M3 in the analysis of mortality between M3 and M6, and M6 in the analysis of mortality between M6 and M12.
bMeasured at ART initiation.
cBetween ART initiation and M3, or between M3 and M6, depending on the analysis.
dSevere-to-moderate malnutrition.
eMild malnutrition.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
However, thehigh mortality rate observed between3and
6 months makes the interpretation of the ‘survivor’
cohort data at 6 months more complex. Needless to say,
the sooner excess mortality can be predicted, the sooner
patient management can be improved, giving more
relevance to the predictive value of weight gain at
3 months compared with 6 months.
The strength of this study lies in the use of data from two
large (>5000 patients overall) and well characterized
cohorts treated with ART in two different developing
countries and with long follow-up (median >2.5 years).
The magnitudes of the effects documented here were
importantandthusworthconsidering.Theincreaseinrisk
of dying was six-fold when comparing patients with less
than or equal to 5% to those with more than 10% weight
gainat3months.CD4cellcountatARTinitiationwasno
longer predictive of mortality between 3 and 6 months
onceweightgainat3monthswastakenintoaccount;thisis
an interesting ﬁnding since in resource-limited settings,
CD4 testing may not always be available.
An attractive feature of weight gain as a monitoring tool
was its‘universality’. Its prognosticvalue on mortality was
not statistically different across programme, sex, WHO
clinical stage at ART initiation, CD4 level at ART
initiation, and type of ART (NVP-based vs. EFV-based)
provided that the initial BMI was taken into account.
Clinicians and healthcare workers need simple clinical
predictors that can be applied equally to large proportions
of patients.
Although our ﬁndings are relevant for patients with low
initial BMI, the number of patients concerned was not
negligible (40% or more of the patients in both
programmes). Additional studies in other countries are
required to conﬁrm that these ﬁndings can be generalized
to other settings.
With ART becoming more widely available, it is hoped
that patients initiate ART at an earlier stage of infection
thus improving their prognosis and making weight
monitoring less useful.
The use of weight gain as a monitoring tool for the
management of HIV-infected patients is particularly
relevant in resource-limited countries because of its
simplicity and low cost. One may object that weight
is subject to measurement error. However, our analysis
was retrospective and based on routine measurements
performed in ﬁeld conditions, in which weight
measurements may not be optimal, as may occur in
study conditions. If anything, the predictive value of
weight on mortality would have been improved had
measurements been free of errors, since measurement
errors were most likely nondifferential with regard to
future mortality. Moreover, sensitivity analyses with
average measurements performed over several visits gave
results identical to those initially obtained.
Weight gain can be of great use in resource-limited
settings, especially when decentralization of HIV care is
required and access to well trained physicians is limited,
for instance, under a scheme in which the ART initiation
visit would be performed by a physician and subsequent
visits by nurses. We chose to examine weight gains at 3
and 6 months, because we speculated these would be
strategictimepointsatwhichpatientscouldbereferredto
a higher level of care in case of suboptimal response
to treatment.
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Table 4. Prognostic factors of mortality after weight gain > –10%
under ART (NU3085).
Crude HR
(95% CI)
Adjusted HR
(95% CI)
Programme
Cambodia 1
Kenya 1.1 (0.8–1.6)
Sex
Men 1 1
Women 0.6 (0.5–0.9) 0.6 (0.4–0.8)
Age at ART initiation (years)
<30 1
30–39 1.2 (0.8–1.8)
40–49 1.0 (0.6–1.6)
 50 1.3 (0.7–2.5)
WHO clinical stage at ART initiation
1–2 0.4 (0.1–2.8) 0.4 (0.1–3.1)
31 1
4 2.9 (2.0–4.2) 2.3 (1.6–3.4)
Delay to weight gain  10% (months)
 61
>6 0.8 (0.3–0.7)
BMI at ART initiation
a (kg/m
2)
 17
c 3.3 (2.0–5.4)
>17 and  18.5
d 2.1 (1.3–3.6)
>18.5 and  20 1.9 (1.1–3.4)
>20 1
Missing 1.3 (0.5–3.3)
BMI at weight gain  10%
b (kg/m
2)
 17 3.9 (2.6–5.7) 2.3 (1.5–3.5)
>17 and  18.5 1.4 (0.8–2.3) 1.0 (0.6–1.6)
>18.5 and  20 1.9 (1.2–2.8) 1.4 (0.9–2.1)
>20 1 1
Missing 1.0 (0.4–2.3) 0.8 (0.4–1.9)
CD4 cell count at ART initiation
a (cells/ml)
 50 1.4 (0.9–2.4)
51–100 1
>100 0.6 (0.3–1.2)
Missing 1.8 (1.0–3.0)
CD4 cell count at weight gain  10%
b (cells/ml)
 100 1
101–200 0.3 (0.2–0.6)
>200 0.3 (0.1–0.5)
Missing 0.6 (0.4–1.0)
Weight loss to  weight at ART initiation
No 1 1
Yes 6.0 (4.3–8.5) 6.6 (4.7–9.3)
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence
interval; HR, hazard ratio; WHO, World Health Organisation.
aMeasured within  1month/þ15 days around ART initiation.
bMeasured within the month preceding a weight gain >10%.
cSevere-to-moderate malnutrition.
dMild malnutrition.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Patients with insufﬁcient weight gain at 3 and 6 months
should undergo extensive clinical and laboratory assess-
ments, as it could be explained by an underlying
opportunistic infection. In these patients, testing in
priority for tuberculosis (TB) could be implemented.
Indeed, the experience from MSF in ﬁve countries
showed a high incidence of TB under ART [28], and TB
remains a leading causes of death in resource-limited
settings [29,30]. Lack of adherence, which is believed to
be the key element to acquisition of antiretroviral drug
resistance [10], could also explain the poor weight gains
observed. In patients with poor weight gain at 3 months,
adherence should be assessed and patients with sub-
optimal adherence undergo counselling to improve it.
Simple methods like pill counts have been identiﬁed as
easy and reliable to assess adherence [31]. In resource-
limited settings, in which the numberof drugs available is
limited, maximizing the duration of existing lines of
treatment, and identifying and addressing the reasons for
poor weight gain, are essential.
Studies are required to better characterize factors
associatedwithpoorweightgain, thatislackof adherence
totreatment,opportunisticinfections,or poor nutritional
intake. Randomized trials are also needed to estimate the
beneﬁt in terms of survival associated with nutritional
supplements.
World Health Organisation recommends looking at
weight gain of at least 10% at 6 months to evaluate ART
programmes [19]. Evaluating weight gain at 6 months
is of interest, but our results, pertaining to individual
and not programmatic evaluation of care, identiﬁed the
3-month time point as more critical for patient
evaluation. In developing countries, where mortality
within the ﬁrst year of ART is high, early detection of
patients with suboptimal ART response is crucial.
The prognostic value of weight gain on mortality was not
restricted to the ﬁrst 6 months of follow-up. Continuing
weight monitoring beyond 6 months was informative.
We showed that more than 60% of patients achieved a
weight gain of at least 10% under ART, but some
subsequentlyexperiencedadecrease inweightequal toor
below their weight at ART initiation. This weight loss
was associated with an increased risk of death, even after
adjustment for BMI level at ART initiation.
Our results should not be interpreted as advocacy for
minimal care and monitoring of patients taking ART in
developing countries. CD4 cell count and viral load
remain the gold standards for patient monitoring, and
everything should be done to make these tests available
in resource-limited settings. However, until they are
broadlyavailable,simplemonitoring toolssuchasweight
measurement can be of great help and should not be
neglected since they provide meaningful patient infor-
mation to healthcare providers.
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